Healthcare Industry News: Novo Nordisk
News Release - June 8, 2006
International Trade Commission Acts on Novo Nordisk Complaint: Launches Investigation of sanofi-aventisPRINCETON, N.J., June 8 (HSMN NewsFeed) -- Novo Nordisk (NYSE: NVO ) announced today that the U.S. International Trade Commission (ITC) has launched an investigation of Sanofi-Aventis's importation of the OptiClik® pen system. Novo Nordisk filed a complaint with the ITC last month alleging that OptiClik and the medication cartridges sold for use with the system infringe a Novo Nordisk U.S. patent and unfairly harm Novo Nordisk's efforts to produce insulin delivery devices in the U.S.
Novo Nordisk is seeking an order from the ITC excluding from entry into the United States further imports of insulin cartridges for use with the OptiClik pen system. The Novo Nordisk patent is part of a large portfolio of patents issued to Novo Nordisk covering insulins and insulin delivery products.
Martin Soeters, president of Novo Nordisk, said, "Novo Nordisk is pleased that the ITC agrees with Novo Nordisk that our competitor's actions warrant an investigation of patent infringement. Our company is an innovator and leader in insulin delivery technology, changing diabetes by providing people with access to the best diabetes care and advanced insulin delivery devices." He added, "As a pioneer in diabetes treatment for 80 years, we have amassed a large patent portfolio that we are committed to defending."
Novo Nordisk's FlexPen® is the leading insulin delivery device in the U.S. and is used with Novo Nordisk's NovoLog® Mix 70/30 (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), NovoLog® (insulin aspart [rDNA origin] injection) and Levemir® (insulin detemir [rDNA origin] injection). Novo Nordisk's insulin delivery device NovoPen® 3 is used with PenFill® insulin cartridges containing analog insulins and human insulins.
Novo Nordisk is a healthcare company with an 80-year history of innovation and achievement in diabetes care. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 22,500 employees in 79 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol "NVO." For global information, visit http://www.novonordisk.com; for United States information, visit http://www.novonordisk-us.com.
Source: Novo Nordisk
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.